ELITech’s COVID, Flu, RSV Multiplex Test Receives CE Mark
December 23, 2020
ELITech Group recently announced its SARS-CoV-2 Plus Elite MGB Kit received CE marking and has been released.
The test kit was developed to distinguish SARS-CoV-2 from other respiratory viruses, including influenza A/B and respiratory syncytial virus types A/B that may have similar symptoms. It runs on the firm’s Elite InGenius platform, as well as other major PCR thermocyclers. The endogenous Internal Control allows confirming the presence and quality of the sample material extracted.
“ELItech is another example of how our BioHive community is responding to COVID-19,” said Kelvyn Cullimore, president and CEO of BioUtah. “We’re proud of how EliTech and Utah’s life sciences companies are working to help keep us safe and healthy.”
Roberto Meda, Vice President MDx, ELITechGroup is excited to offer such an important multiplex Sample-to-Result solution for the detection of the SARS-CoV-2, Flu A, Flu B, and RSV viruses. This achievement was made possible by the dedication and collaboration of all EG teams involved.
Recent News
- RefloDx Closes $2 Million Seed Round to Advance Noninvasive Testing for Chronic Throat and Voice Symptoms
- Myriad Genetics Releases New MONSTAR-SCREEN-3 Data Demonstrating the Potential of Ultra-Sensitive MRD Detection in Colorectal and Pancreatic Cancers
- Ultragenyx sells second rare pediatric PRV in a week for $203M
- Co-Diagnostics’ Joint Venture CoMira Diagnostics Invited by Saudi Ministry to Participate in Strategic Manufacturing Forum
- Route 92 Medical Announces $100 Million Corporate Debt Facility
- Myriad Genetics and Labcorp Announce Definitive Agreement for Myriad to Sell Prenatal Health Testing Business to Labcorp
